G1 Therapeutics Inc at JPMorgan Healthcare Conference Transcript
&-
Alright. Let's go ahead and get started, and welcome everyone to the 42nd Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, Priyanka Grover, Laura Hall and Malcolm Kuna. Our next presenting company is G1. And presenting on behalf of the Company, we have CEO, Jack Bailey. Jack?
Thank you, Anupam. I am very excited to be here today because we believe 2024 holds enormous potential for G1, both as we return co-sell back to stronger growth in our initial indication of extensive-stage small cell lung cancer following the resolution of the national supply platinum supply shortage this past year, but more importantly, the opportunity to become triple negative breast cancer leader first by providing potentially a new therapeutic option for women suffering from first line metastatic triple-negative breast cancer, pending.
Our Phase 3 readout
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
